Oncology and Hematology

Episodes 129-144 of 386

Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
MinuteCE®
Clinical evidence driving guidelines for immunotherapy in the neoadjuvant and adjuvant settings of NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
MinuteCE®
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
MinuteCE®
Guidelines-recommended first-line treatment with immunotherapy-based regimens in PD-L1- positive metastatic NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
MinuteCE®
Innovations in Oncology Learning Center From Guidelines to Practice: Lung Cancer
1.00 credit 10 episodes
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 credit 10 episodes
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
MinuteCE®
Emerging and practice-changing directions in NSCLC within the perioperative and locally advanced settings
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
MinuteCE®
Guideline recommendations for first-line treatment of advanced NSCLC with targeted therapies
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Insights from global key opinion leaders on optimizing patient care in NSCLC
Insights from global key opinion leaders on optimizing patient care in NSCLC
MinuteCE®
Insights from global key opinion leaders on optimizing patient care in NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
MinuteCE®
Incorporation of guidelines-concordant care for advanced NSCLC with second-line targeted therapies
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
MinuteCE®
Guidelines-recommended targeted therapies as second-line treatment options for patients with metastatic NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
CAR T-Cell Therapy for R/R Mantle Cell Lymphoma: Key Considerations
CAR T-Cell Therapy for R/R Mantle Cell Lymphoma: Key Considerations
Project Oncology®
CAR T-Cell Therapy for R/R Mantle Cell Lymphoma: Key Considerations
- Chenyu Lin, MD
- Charles Turck, PharmD, BCPS, BCCCP
Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy
Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy
Project Oncology®
Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy
- Charles Turck, PharmD, BCPS, BCCCP
- Hope S. Rugo, MD, FASCO
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
MinuteCE®
Incorporation of guidelines-concordant immunotherapy in the perioperative setting of NSCLC
1.00 program credit
- Luis Paz-Ares, MD, PhD
- Helena Yu, MD
- Matthew Gubens, MD, MS
1.00 program credit
Holistic AI Models Revolutionizing Cancer Detection and Treatment
Holistic AI Models Revolutionizing Cancer Detection and Treatment
Clinician's Roundtable
Holistic AI Models Revolutionizing Cancer Detection and Treatment
Navigating mCRPC Treatment: A Look at Abiraterone and Enzalutamide
Navigating mCRPC Treatment: A Look at Abiraterone and Enzalutamide
Project Oncology®
Navigating mCRPC Treatment: A Look at Abiraterone and Enzalutamide
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
Project Oncology®
Optimizing mCRPC Care: Treatment Selection and Sequencing Strategies
- Charles Turck, PharmD, BCPS, BCCCP
- Hannah McManus, MD
- Andrew Armstrong, MD, MSc
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
CME/CE
Empowering Choices: Navigating Early-Stage HR+, HER2- Breast Cancer with CDK4/6 Inhibition
0.25 credits
- Joyce O'Shaughnessy, MD
0.25 credits